Plain-English translation of NCT06830694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding tarlatamab, a newer type of immunotherapy drug, to standard chemotherapy and another immunotherapy (atezolizumab) can help people with a rare type of lung cancer transformation. The study focuses on patients whose adenocarcinoma lung cancer changed into small cell lung cancer after their original EGFR-targeted therapy stopped working. Researchers hope this combination will help people live longer and keep their cancer under control for a longer time.
When lung cancer transforms into small cell lung cancer after previous treatment, patients typically survive only 9 to 10 months even with current standard treatments. Current therapies help some patients, but the cancer usually starts growing again within about 5 months, so doctors are looking for better maintenance strategies and new targets to attack the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive four cycles of combined chemotherapy and immunotherapy over 12 weeks, with treatments given every 3 weeks. Each cycle includes intravenous infusions of three drugs over a few days. After completing these four cycles, you will move into a maintenance phase where you receive the new medication (tarlatamab) twice per week and the other immunotherapy drug once per month for as long as the treatment is helping and you tolerate it well. You will have regular blood tests, imaging scans, and doctor visits to monitor how you're responding and check for side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
South Korea